Orthofix Medical Rises 9.5% as CMS Reverses Reimbursement Cut

Orthofix Medical Inc. (OFIX) shares surged 9.5% on July 23, 2026, following an announcement from the Centers for Medicare & Medicaid Services (CMS) that it reversed a previously proposed 3.3% payment cut for certain spinal fusion procedures. The final Physician Fee Schedule rule, published that day, reinstates higher reimbursement rates for spinal implants and bone growth stimulators, key product categories for the company. The reversal concludes a seven-month review period that had created significant uncertainty for the spinal device sector.

Context — [why this matters now]

The proposed cut, initially outlined in December 2025, targeted specific Diagnosis-Related Groups (DRGs) for complex spinal fusions. CMS had argued the changes were necessary to align payments with procedural efficiencies. Industry pushback was immediate and coordinated. The Medical Device Manufacturers Association (MDMA) submitted a 120-page comment in February 2026, arguing the cuts would disproportionately impact patient access to innovative technologies in rural and underserved areas.

This decision arrives amid a stabilizing interest rate environment, with the 10-year Treasury yield near 4.2%. The healthcare sector has underperformed the broader S&P 500 index year-to-date, making positive regulatory news a potential catalyst for a reversal. The last significant positive CMS ruling for device makers occurred in 2021, when the agency expanded coverage for robotic-assisted surgery, lifting Intuitive Surgical (ISRG) shares by over 8% in a single session.

The catalyst chain began with the proposed rule's release, triggering a 15% decline in OFIX shares over the subsequent two weeks. Lobbying efforts intensified throughout the second quarter, culminating in a bipartisan letter from 35 members of Congress to CMS in June 2026, urging a reevaluation. The final rule's publication confirms that these efforts successfully influenced policy.

Data — [what the numbers show]

Orthofix's stock price closed at $14.75 on July 23, a single-day gain of $1.28. Trading volume reached 1.8 million shares, over four times the 90-day average of 425,000 shares. The company's market capitalization increased by approximately $65 million to a total of $750 million.

The reimbursement reversal directly affects procedures utilizing Orthofix's flagship products, including the M6-C artificial cervical disc and its bone growth stimulation systems. These products are central to spinal fusion surgeries, which have an average Medicare reimbursement rate of approximately $25,000 per procedure. The 3.3% cut would have reduced that by about $825, negatively impacting hospital purchasing decisions.

A comparison of peer performance on July 23 reveals the news had a sector-wide effect.

Company	Ticker	Price Change
Orthofix Medical	OFIX	+9.5%
NuVasive	NUVA	+2.1%
Globus Medical	GMED	+1.8%
S&P 500 Index	SPX	+0.3%

Despite the rally, Orthofix shares remain down 12% year-to-date, significantly trailing the broader health care select sector SPDR Fund (XLV), which is up 5% over the same period.

Analysis — [what it means for markets / sectors / tickers]

The CMS decision removes a major overhang on Orthofix's revenue stream, which derives over 40% of its sales from Medicare-related payments. Analysts at BTIG noted that the reversal could add $12-$15 million to the company's top line in fiscal year 2027, improving its path to profitability. The positive sentiment also buoyed other spine-focused companies like NuVasive (NUVA) and Globus Medical (GMED), which saw gains of 2.1% and 1.8%, respectively, as the ruling sets a favorable precedent for the entire segment.

A key risk to this optimistic outlook is procedure volume. While reimbursement rates are stable, elevated hospital labor costs and staffing shortages could still suppress the number of elective spinal surgeries performed. Orthofix's higher debt-to-equity ratio of 0.65, compared to the industry average of 0.45, also leaves it more vulnerable to interest rate fluctuations than some peers.

Positioning data from July 23 shows institutional buyers were the primary drivers of the rally, with block trades accounting for 45% of the day's volume. Short interest had climbed to 8% of the float prior to the announcement, suggesting a portion of the move was fueled by short covering. Flow into the iShares U.S. Medical Devices ETF (IHI) also ticked higher, indicating a broader reassessment of regulatory risk for the subsector. For more on how regulatory shifts drive medtech valuations, see our analysis of the sector.

Outlook — [what to watch next]

The primary near-term catalyst for Orthofix is its Q2 2026 earnings report, scheduled for August 6, 2026. Management's commentary on procedure volume trends and updated annual guidance will be scrutinized for confirmation that the CMS news is translating into operational strength. Any deviation from expected growth could quickly reverse the recent gains.

Investors should monitor the $15.00 price level for OFIX shares, which has acted as technical resistance three times over the past year. A sustained break above this level on high volume would signal strong buyer conviction. Conversely, a fall below the 50-day moving average near $13.50 would indicate the rally is losing momentum.

The next major regulatory event for the industry is the CMS Hospital Outpatient Prospective Payment System (OPPS) proposed rule, expected in mid-November 2026. This rule will address reimbursement for ambulatory surgery centers, another critical channel for spinal device companies. Any proposed changes there will be the next test of the regulatory environment.